Prelude Capital Management, LLC Biogen Inc. Transaction History

Prelude Capital Management, LLC

$1.39 Billion
Q2 2024

A detailed history of Prelude Capital Management, LLC transactions in Biogen Inc. stock. As of the latest transaction made, Prelude Capital Management, LLC holds 2,523 shares of BIIB stock, worth $438,472. This represents 0.04% of its overall portfolio holdings.

Number of Shares

2,523

Previous 1,838 37.27%

Holding current value

$438,472

Previous $396,000 47.47%

% of portfolio

0.04%

Previous 0.02%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$190.52 - $236.72 $130,506 - $162,153	685 Added 37.27%	2,523 $584,000
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $8,056 - $10,172	38 Added 2.11%	1,838 $396,000
Q4 2023 Feb 14, 2024	SELL	$222.59 - $267.94 $911,951 - $1.1 Million	-4,097 Reduced 69.48%	1,800 $465,000
Q3 2023 Nov 14, 2023	SELL	$253.3 - $285.89 $29,129 - $32,877	-115 Reduced 1.91%	5,897 $1.52 Million
Q2 2023 Aug 14, 2023	SELL	$275.25 - $318.06 $1.46 Million - $1.69 Million	-5,310 Reduced 46.9%	6,012 $1.71 Million
Q1 2023 May 15, 2023	BUY	$256.56 - $292.34 $890,776 - $1.02 Million	3,472 Added 44.23%	11,322 $3.15 Million
Q4 2022 Feb 14, 2023	BUY	$252.44 - $306.72 $521,793 - $633,990	2,067 Added 35.74%	7,850 $2.17 Million
Q3 2022 Nov 14, 2022	BUY	$194.69 - $268.46 $1.13 Million - $1.55 Million	5,783 New	5,783 $1.54 Million
Q3 2021 Nov 15, 2021	SELL	$282.99 - $369.05 $1.4 Million - $1.83 Million	-4,957 Reduced 82.66%	1,040 $294,000
Q2 2021 Aug 16, 2021	BUY	$259.0 - $414.71 $1.21 Million - $1.94 Million	4,666 Added 350.56%	5,997 $2.08 Million
Q2 2020 Aug 14, 2020	SELL	$258.66 - $342.55 $270,299 - $357,964	-1,045 Reduced 43.98%	1,331 $356,000
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $361,872 - $459,039	-1,346 Reduced 36.16%	2,376 $752,000
Q4 2019 Feb 14, 2020	BUY	$220.06 - $304.07 $775,491 - $1.07 Million	3,524 Added 1779.8%	3,722 $1.1 Million
Q3 2019 Nov 14, 2019	SELL	$217.44 - $243.88 $492,284 - $552,144	-2,264 Reduced 91.96%	198 $46,000
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $219,458 - $277,967	788 Added 47.07%	2,462 $741,000
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $1.24 Million - $1.62 Million	-4,216 Reduced 71.58%	1,674 $591,000
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $1.27 Million - $1.52 Million	4,943 Added 521.96%	5,890 $1.71 Million
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $746,573 - $1.06 Million	-2,870 Reduced 75.19%	947 $259,000
Q4 2017 Feb 14, 2018	SELL	$307.64 - $344.58 $1.15 Million - $1.29 Million	-3,746 Reduced 49.53%	3,817 $1.22 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $2.13 Million - $2.49 Million	7,563	7,563 $2.37 Million

Others Institutions Holding BIIB

# of Institutions

1,018

Shares Held

128M

Call Options Held

1.22M

Put Options Held

1.4M

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Account

Prelude Capital Management, LLC Biogen Inc. Transaction History